Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin.

Effects of atorvastatin and pravastatin on glucose tolerance in mildly induced diabetic rats by streptozotocin at 24 mg/kg, i.v. were studied. Non-diabetic and diabetic rats were given orally 0.5% carboxymethylcellulose (control), 8 mg/kg atorvastatin or 8 mg/kg pravastatin once a day for 6 weeks. An oral glucose tolerance test (OGTT) was carried out 1, 2, 3, and 6 weeks after the administration. The blood glucose and plasma insulin levels measured before OGTT in the diabetic rats were not different from those in the non-diabetic rats. However, the hyperglycemic response to OGTT in the diabetic rats significantly exceeded that in the non-diabetic rats. The plasma insulin increased by OGTT in the diabetic rats appeared to be lower than that in the non-diabetic rats. Statin treatments for 1 week did not modify the OGTT-induced hyperglycemia appreciably, although there were some significant differences. More than 2 weeks after administration, the blood glucose levels at several time points after a glucose intake in the atorvastatin-treated diabetic rats were significantly higher than the respective levels in the control diabetic rats. Neither atorvastatin nor pravastatin modified the OGTT-induced insulin secretion. Statins, especially atorvastatin, may influence the glucose tolerance in mildly induced diabetic rats without alterations of insulin secretion.

[1]  Antonio Abbate,et al.  Atherothrombosis, inflammation, and diabetes. , 2003, Journal of the American College of Cardiology.

[2]  H. Nagase,et al.  Antioxidative effects of fluvastatin and its metabolites against DNA damage in streptozotocin-treated mice. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[3]  J. Bauersachs,et al.  Glucose increases endothelial-dependent superoxide formation in coronary arteries by NAD(P)H oxidase activation: attenuation by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin. , 2002, Diabetes.

[4]  J. López-Miranda,et al.  Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes. , 2002, Diabetes.

[5]  K. Ichihara,et al.  Disparity between angiographic regression and clinical event rates with hydrophobic statins , 2002, The Lancet.

[6]  Peter Libby,et al.  Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. , 2002, JAMA.

[7]  W. Insull,et al.  Comparison of efficacy and safety of atorvastatin (10 mg) with simvastatin (10 mg) at six weeks , 2001 .

[8]  P W Macfarlane,et al.  Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study , 2001, Circulation.

[9]  M. Barbagallo,et al.  Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. , 2000, Atherosclerosis.

[10]  M. Nakata,et al.  Inhibition by simvastatin, but not pravastatin, of glucose‐induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L‐type Ca2+ channels in rat islet β‐cells , 1999, British journal of pharmacology.

[11]  P. Neuvonen,et al.  Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole , 1998, Clinical pharmacology and therapeutics.

[12]  K. Ichihara,et al.  Lipid peroxidation in the pancreas and other organs in streptozotocin diabetic rats. , 1997, Japanese journal of pharmacology.

[13]  S. Corey,et al.  Lovastatin disrupts early events in insulin signaling: a potential mechanism of lovastatin's anti-mitogenic activity. , 1994, Biochemical and biophysical research communications.

[14]  S. Haffner,et al.  Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? , 1990, JAMA.

[15]  O. Ganda,et al.  Studies on Streptozotocin Diabetes , 1976, Diabetes.

[16]  C. Rerup.  Drugs producing diabetes through damage of the insulin secreting cells. , 1970, Pharmacological reviews.

[17]  A. Dahlqvist.  Determination of maltase and isomaltase activities with a glucose-oxidase reagent. , 1961, The Biochemical journal.

[18]  Y. Gotō,et al.  The Spontaneous-Diabetes Rat: A Model of Noninsulin Dependent Diabetes Mellitus , 1981 .